Ranibizumab Versus Aflibercept for CRVO in Young Patients.

South Valley University40 enrolled

Overview

this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old

This is a prospective randomized interventional study, Forty eyes of forty patients younger than 50 years with macular edema due to non-ischemic CRVO were enrolled in the study. Patients will be randomized into 2 groups. First group will receive intravitreal injection of Ranibizumab 0.5 mg\\0.1ml. the second group will receive intravitreal injection of 2.0 mg\\0.1 ml Aflibercept. All patients will be followed up for 12 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

Interventions

intravitreal injection of RanibizumabPROCEDURE

intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)

intravitreal injection of AfliperceptPROCEDURE

intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)

RanibizumabDRUG

Ranibizumab

Eligibility

Sex: ALLMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients younger than 50 years with macular edema due to non-ischemic CRVO Exclusion Criteria: Other conditions that might affect the macula as 1. diabetic retinopathy, intraocular inflammation, age related macular degeneration, patients with solar or radiation retinopathy, 2. patients with ischemic type CRVO and patients who had recent intraocular surgery. 3. patients who had previous intravitreal injections, ophthalmic laser surgeries. 4. patients with dense cataracts whom fundus was difficult to scan. 5. Patients who were lost to follow up visits were also excluded

Locations (1)

Ahmed Ali Ahmed Amer

Qina, Qena Governorate, Egypt

RECRUITING

Outcomes

Primary Outcomes

Best corrected visual acuity BCVA

change BCVA after injection

Time frame: at 12 months post-injection

Secondary Outcomes

reduction of macular edema

change in central subfield macular thickness CST on OCT

Time frame: at 12 months post-injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.